Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…
HOME > BUSINESS
BUSINESS
- ASKA to Transfer Menoaid Hot Flash Drug to Hisamitsu
June 4, 2019
- Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
June 4, 2019
- Takeda Pledges 1 Billion Yen in Global Fund, 2nd Investment in Fighting for HIV, TB, and Malaria
June 4, 2019
- Chugai’s Gene Mutation Analysis Program Now Available in Japan
June 4, 2019
- Rakuten Medical Sets Up Outposts in Netherlands, Taiwan
June 3, 2019
- Janssen Japan Files Erleada for Castration-Sensitive Prostate Cancer
June 3, 2019
- Additional OS Data to Be Added to Xospata’s US Label: Astellas
June 3, 2019
- Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
- Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
May 31, 2019
- Novartis, Sumitomo Dainippon to Jointly Promote Equa, EquMet
May 31, 2019
- Teva Takeda Yakuhin Voluntary Recalls Menatetrenone Capsules
May 31, 2019
- Application for Mitsubishi Tanabe’s ALS Drug Pulled in EU
May 31, 2019
- Ono Files Opdivo for Second-Line Treatment of Esophageal Cancer
May 31, 2019
- Otsuka Shoots for Pharma Sales of 1.08 Trillion Yen in 2023
May 31, 2019
- Tokyo Court Dismisses Genentech’s Bid to Block Rituxan Biosimilar
May 30, 2019
- Japan Drug Firms’ Average Overseas Sales Ratio Nearly 50%, Offshore Biz Remains Way to Go as Home Market Falters: Tally
May 30, 2019
- Japan’s 1st ADA Deficiency Treatment Revcovi Now Available: Teijin Pharma
May 30, 2019
- Janssen Launches Simponi Autoinjector in Japan, Mitsubishi Tanabe in Charge of Distribution
May 30, 2019
- MSD/Bayer’s Rosuzet Now Available in Japan
May 29, 2019
- Takeda to Launch New Manufacturing Facility for Leuplin; Aims to Maintain Its 110 Billion Yen Sales
May 29, 2019
ページ
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…